Some personal (aka professional) news: I'm starting a new position as Chief Scientific Officer at Ginkgo Bioworks 🧵

Today on Foundry Theory! Why we need both smart design and large datasets to engineer biology effectively. hubs.la/Q02Lt-cd0

Today I’m so excited to launch The Biocreative Index, a directory of people working at the intersection of biology and creative disciplines. Want to join the index, be connected to our community, or contribute a resource? Head over to our website for more: biocreativeindex.com

Mitch Wolfe, MD, VP of Global Engagement and Governance, Ginkgo Bioworks and former CMO of CDC, offers some insights on #mpox including the benefits of declaring a global emergency, transmission, and considerations for both the US public and clinicians. contagionlive.com/view/the-signi…

Using AI from Google Cloud, Ginkgo Bioworks is making biology easier to engineer. That means faster medicines, better crops, and more.

Companies are moving therapeutic testing from plastic wells into pooled in vivo screening, generating physiologically relevant data by screening many drug candidates at once in a single animal nature.com/articles/s4158…

We will hear from Ed Mason from JetZero Australia , Dr Natalie Curach, from Ginkgo Bioworks and Jason Crusan from Woodside Energy; as well as a keynote from LanzaTech Global's Dr Sean Simpson.

Yes! Pooled tech is great for many applications -- it's not a replacement for arrayed tests in wells, but a great complement. This article talks about our million-member CAR-T library tested in mice in partnership with WARF. As with anything you read about @ginkgo reach out

Today we’re excited to announce our new partnership with Vitales, a subsidiary of Uby Agro, to accelerate the development and launch of two new Generation 1 biocontrol products. hubs.ly/Q02N065M0

In response to the growing #mpox threat and World Health Organization (WHO)'s public health emergency, we are actively tracking the risk and spread of mpox globally and in central Africa. Beyond analyzing travel patterns and transmission dynamics, Ginkgo has deployed biosurveillance efforts that show

Foundry Theory Time! This week Jake talks about how the AI era brings a new perspective to old comparisons between biology and stamp collecting. hubs.la/Q02N3zn60

Super excited to officially launch our newest product line -- Ginkgo Automation!🤖🧬🤖 Over the past 10 years Ginkgo Bioworks has built a ton of amazing technologies from automation to long DNA construction to complex -omics to proprietary data and AI assets. These tools had been kept

(still engineering cells too)

We’ve been super happy being pilot customers of Ginkgo Bioworks automation. The RACs have been incredibly enabling, allowing us to run several hundred thousand synthetic chem and mammalian assays a month across many different drug programs.

Visiting NYC this week and would love to meet with teams building in AI x Bio. DM if you'd like to meet up - I’m around after Labor Day. Our team at Ginkgo is building foundation models in biology and would love to partner on data generation or compute.

Congrats Ginkgo Bioworks ! We started working with Ginkgo a couple of years ago to build out our automated screening facility and I can't imagine where we would be without it.

Agreed that experimental throughout matters for AI. If you are leveraging AI protein models @ginkgo offers both outsourced large scale data generation in ginkgo’s automated labs as well as in-house automation deployments in your lab. No royalties and data generated is owned

In this week's issue of the Better Bioeconomy newsletter: 🇮🇳 India’s bioeconomy gets major boost 🇬🇧 UK invests £38M in alt protein hub 💰 $66M precision fermentation deal 🇩🇰 Scientists produce alt proteins from food and pharma wastewater 🇧🇷 Ginkgo Bioworks 🤝 Vitales And more ⬇️

"Google Cloud’s Shweta Maniar is on a mission to revamp drug discovery with the power of generative AI, the trendy type of AI that can create new content." “Ginkgo Bioworks is leveraging Google Cloud to fine-tune and train large language models for a variety of tasks,” Maniar

This week on Foundry Theory! What is it about biotech R&D that makes collaboration challenging? How can we make it easier? hubs.la/Q02NTCsY0